Fig. 4 | Cellular & Molecular Immunology

Fig. 4

From: The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Fig. 4

APG-2575 effectively repolarized M2-like macrophages to the M1 phenotype. A A heatmap of the normalized mean-centered mRNA expression levels of genes associated with M1 or M2 macrophages in the control and APG-2575 treatment groups. B, C IL-4-activated BMDMs were treated with or without APG-2575. The mRNA expression of M1/M2-related markers was analyzed. D, E Quantification of CD86, MHC-II and CD206 expression in IL-4-activated BMDMs with or without APG-2575 treatment. F, G Quantification of CD86, HLA-DR and CD206 expression in IL-4-activated CD14+ monocyte-derived macrophages with or without APG-2575 treatment. H–K Flow cytometric analysis of CD86 and CD206 in TAMs from hu-CD34+ and C57BL/6 mice treated with PBS or APG-2575. L, M Immunohistochemical staining of CD86 and CD206 in humanized CD34+ mouse xenograft tumors. N, O Immunohistochemical staining of CD86 and CD206 in C57BL/6 mouse xenograft tumors

Back to article page